Niagen Bioscience ( ($NAGE) ) has shared an update. On December 16, 2025, Niagen Bioscience’s subsidiary ChromaDex, Inc. entered into an ...

Niagen Bioscience (NAGE) is grabbing attention after two major announcements: positive clinical trial results for its patented Niagen ingredient in long COVID, and the debut of Tru Niagen Beauty, ...

This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industryLOS ANGELES--(BUSINESS WIRE)--$NAGE ...

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Are you NAD-ing? Well, if you aren’t, someone else is. Most ...

There’s no such thing as a magic longevity pill. But NAD supplements might just be the next closest thing to a capsule you can swallow to increase your healthspan. Nicotinamide adenine dinucleotide, ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

The Biden administration will propose a new rule to ban credit score companies from considering medical debt when they compile Americans' credit reports. The company expects to deliver $120 to $140 ...

Scottsdale-based agency recognized for excellence in crisis communications, corporate communications, public affairs and traditional… This year marks a major milestone for The McRae Agency as it ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Niagen Bioscience, Inc. (Nasdaq: NAGE), the global leader in NAD+ (nicotinamide ...

Niagen Bioscience, Inc. (NAGE) profitability grade and underlying metrics. Quant Ratings. Charts: gross margin, EBIT, Net Income, EBITDA, ROE, ROA, etc.